SHSE:601607 (China)
Business Description
Shanghai Pharmaceuticals Holding Co Ltd
NAICS : 446110
No. 200 Taicang Road, Shanghai Pharmaceutical Building, Shanghai, CHN, 200020
Compare
Compare
Traded in other countries / regions
601607.China
•
S1R.Germany
•
02607.Hong Kong
•
SHPMF.USA
Description
Shanghai Pharmaceuticals is a vertically integrated Chinese healthcare company that operates drug manufacturing, distribution, and retail pharmacy businesses in mainland China. It is the second- largest distributor by revenue, with a strong presence in Eastern China.
Financial Strength
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 1 | |||||
| Equity-to-Asset | 0.35 | |||||
| Debt-to-Equity | 0.57 | |||||
| Debt-to-EBITDA | 4.22 | |||||
| Interest Coverage | 5.22 | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | 2.18 | |||||
| Beneish M-Score | -2.34 | |||||
| WACC vs ROIC | ||||||
Growth Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | 10.5 | |||||
| 3-Year EBITDA Growth Rate | 15.6 | |||||
| 3-Year EPS without NRI Growth Rate | 9.3 | |||||
| 3-Year FCF Growth Rate | -7.7 | |||||
| 3-Year Book Growth Rate | 8.2 | |||||
| Future 3-5Y EPS without NRI Growth Rate Industry Rank | -0.16 | |||||
| Future 3-5Y Total Revenue Growth Rate Industry Rank | 8.16 |
Momentum Rank
5/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 59.48 | |||||
| 9-Day RSI | 48.5 | |||||
| 14-Day RSI | 44.61 | |||||
| 6-1 Month Momentum % | -6.38 | |||||
| 12-1 Month Momentum % | -5.6 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 1.42 | |||||
| Quick Ratio | 1.15 | |||||
| Cash Ratio | 0.38 | |||||
| Days Inventory | 47.07 | |||||
| Days Sales Outstanding | 97.79 | |||||
| Days Payable | 80.11 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Dividend Yield % | 2.45 | |||||
| Dividend Payout Ratio | 0.32 | |||||
| 3-Year Dividend Growth Rate | 8.1 | |||||
| Forward Dividend Yield % | 2.45 | |||||
| 5-Year Yield-on-Cost % | 3.53 |
Profitability Rank
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 13.08 | |||||
| Operating Margin % | 3.69 | |||||
| Net Margin % | 1.91 | |||||
| ROE % | 8.2 | |||||
| ROA % | 2.57 | |||||
| ROIC % | 7.53 | |||||
| ROC (Joel Greenblatt) % | 20.12 | |||||
| ROCE % | 12.13 | |||||
| Years of Profitability over Past 10-Year | 10 |
GF Value Rank
10/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PE Ratio | 11.57 | |||||
| Forward PE Ratio | 12.92 | |||||
| PE Ratio without NRI | 11.57 | |||||
| Shiller PE Ratio | 12.56 | |||||
| Price-to-Owner-Earnings | 25.23 | |||||
| PEG Ratio | 0.98 | |||||
| PS Ratio | 0.22 | |||||
| PB Ratio | 0.75 | |||||
| Price-to-Tangible-Book | 1.03 | |||||
| Price-to-Operating-Cash-Flow | 13.32 | |||||
| EV-to-EBIT | 6.49 | |||||
| EV-to-Forward-EBIT | 7.38 | |||||
| EV-to-EBITDA | 6.49 | |||||
| EV-to-Forward-EBITDA | 5.92 | |||||
| EV-to-Revenue | 0.26 | |||||
| EV-to-Forward-Revenue | 0.25 | |||||
| EV-to-FCF | -127.33 | |||||
| Price-to-Projected-FCF | 0.73 | |||||
| Price-to-DCF (Earnings Based) | 0.66 | |||||
| Price-to-Median-PS-Value | 0.49 | |||||
| Price-to-Peter-Lynch-Fair-Value | 1.22 | |||||
| Price-to-Graham-Number | 0.73 | |||||
| Price-to-Net-Current-Asset-Value | 2.8 | |||||
| Earnings Yield (Greenblatt) % | 15.41 | |||||
| Forward Rate of Return (Yacktman) % | 12.12 |
Guru Trades
See DetailsEMBED
SAVE
Insider Trades
See DetailsEMBED
SAVE
Executives
EMBED
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil ¥) | 221,122.489 | ||
| EPS (TTM) (¥) | 1.48 | ||
| Beta | 0.58 | ||
| Volatility % | 45.32 | ||
| 14-Day RSI | 44.61 | ||
| 14-Day ATR (¥) | 0.282698 | ||
| 20-Day SMA (¥) | 17.245 | ||
| 12-1 Month Momentum % | -5.6 | ||
| 52-Week Range (¥) | 16.41 - 28.64 | ||
| Shares Outstanding (Mil) | 3,696.41 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Shanghai Pharmaceuticals Holding Co Ltd Filings
| Document | Form | Filing Date | ||
|---|---|---|---|---|
| No Filing Data | ||||